Safety and efficacy of S 38093 and donepezil, during 4 weeks, in patients with mild to moderate Alzheimer's Disease. An international, multi-centre, randomised, double-blind, placebo controlled, phase II add-on study. [Seguridad y eficacia de S 38093 y donepezilo, en pacientes con enfermedad de Alzheimer leve a moderada, durante 4 semanas. Estudio de fase II, de asociación, internacional, multicéntrico, aleatorizado, doble ciego, controlado frente a placebo].

Trial Profile

Safety and efficacy of S 38093 and donepezil, during 4 weeks, in patients with mild to moderate Alzheimer's Disease. An international, multi-centre, randomised, double-blind, placebo controlled, phase II add-on study. [Seguridad y eficacia de S 38093 y donepezilo, en pacientes con enfermedad de Alzheimer leve a moderada, durante 4 semanas. Estudio de fase II, de asociación, internacional, multicéntrico, aleatorizado, doble ciego, controlado frente a placebo].

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2012

At a glance

  • Drugs Donepezil; S 38093
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Jun 2012 Additional trial location (Spain) added as reported by European Clinical Trials Database.
    • 08 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top